In the field of cell and gene therapy, which is considered a next-generation drug, an M&A worth 3.4 trillion won was completed. Domestic biopharmaceutical companies are conducting R&D in the field of cell and gene therapy as a future food source. CDMO companies are entering the CDMO business for cell and gene therapy through M&A and factory expansion.

◆ 3.4 trillion won worth of M&A

According to the industry on the 4th, Sartorius, a German-based global biopharmaceutical company, announced on the 31st of last month (local time) that it would acquire French Polyplus, a producer of raw materials for cell and gene therapy, for 2.4 billion euros (approximately 3.4 trillion won). Sartori